Sacituzumab govitecan Uses, Side Effects & Warnings - Drugs.com

Skip to main content
Print
Save

# Sacituzumab govitecan

Generic name: sacituzumab govitecan [ SAK-i-TOOZ-ue-mab-GOE-vi-TEE-kan ]
Brand name: Trodelvy
Dosage form: intravenous powder for injection (hziy 180 mg)
Drug class: Miscellaneous antineoplastics

Medically reviewed by Drugs.com on Aug 26, 2021. Written by Cerner Multum.

## What is sacituzumab govitecan?

Sacituzumab govitecan is used to treat HR-negative and HER2-negative (sometimes called triple-negative) breast cancer, after treatment with at least two other cancer medications.

Sacituzumab govitecan is used to treat cancers of the bladder and urinary tract, after treatment with a platinum cancer medicine and an immunotherapy treatment.

Sacituzumab govitecan is used when the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery.

Sacituzumab govitecan may also be used for purposes not listed in this medication guide.

## Warnings

You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, chills, burning when you urinate, a cough, or trouble breathing.

Sacituzumab govitecan commonly causes diarrhea. Severe diarrhea can lead to dehydration, which may require medical treatment.

Tell your doctor right away the first time you have diarrhea while receiving sacituzumab govitecan, or if you have black or bloody stools, if you feel light-headed, if you can't keep liquids down because of vomiting, or if you can't get your diarrhea to stop within 24 hours.

## Before taking this medicine

You should not be treated with sacituzumab govitecan if you have ever had a severe allergic reaction to it.

Tell your doctor if you have ever had:

- liver disease; or

- if you've been told that you carry a gene called UGT1A1*28, which may increase your risk of getting infections while using sacituzumab govitecan.

Sacituzumab govitecan can harm an unborn baby if the mother or the father is using this medicine.

- If you are a woman, you may need a pregnancy test to make sure you are not pregnant. Use birth control while using this medicine and for at least 6 months after your last dose.

- It may be harder for you to get pregnant while you are using this medicine. You should still use birth control to prevent pregnancy because the medicine can harm an unborn baby.

- If you are a man, use birth control if your sex partner is able to get pregnant. Keep using birth control for at least 3 months after your last dose.

- Tell your doctor right away if a pregnancy occurs.

Do not breastfeed while using this medicine, and for at least 1 month after your last dose.

## Related/similar drugs

Ibrance, Keytruda, Arimidex, pembrolizumab, nivolumab, Xeloda, Femara

## How is sacituzumab govitecan given?

Sacituzumab govitecan is injected into a vein by a healthcare provider.

Sacituzumab govitecan is given in a 21-day treatment cycle. You will receive an injection only on certain days of this cycle.

sacituzumab govitecan must be given slowly over 1 to 3 hours.

You will be watched for a short time to make sure you do not have an allergic reaction.

You may be given other medications to help prevent serious side effects or an allergic reaction. Keep using these medicines for as long as your doctor has prescribed.

Sacituzumab govitecan commonly causes diarrhea. Severe diarrhea can lead to dehydration, which may require medical treatment. Tell your doctor right away the first time you have diarrhea while receiving this medicine.

You may get infections more easily, even serious or fatal infections. You will need frequent medical tests. Your cancer treatments may be delayed based on the results.

Your doctor will determine how long to treat you with this medicine.

## What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your sacituzumab govitecan injection.

## What happens if I overdose?

In a medical setting an overdose would be treated quickly.

## What should I avoid while receiving sacituzumab govitecan?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

## Sacituzumab govitecan side effects

sacituzumab govitecan can cause severe or life-threatening allergic reactions.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection or within 24 hours afterward. Tell your medical caregivers if you feel dizzy, light-headed, itchy, sweaty, or have a fever, chills, trouble breathing, or swelling in your face or throat.

You may get infections more easily, even serious or fatal infections. Call your doctor right away if you have signs of infection such as:

- pain or burning when you urinate;

- low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or

- low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing.

Sacituzumab govitecan can cause severe diarrhea. Tell your doctor right away if you have:

- diarrhea (the first time it occurs);

- diarrhea lasting longer than 24 hours (even if you use anti-diarrhea medicine);

- black or bloody stools;

- severe or ongoing vomiting, especially if you can't keep liquids down; or

- a light-headed feeling, like you might pass out.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of sacituzumab govitecan may include:

- diarrhea, nausea, vomiting;

- stomach pain, loss of appetite, constipation;

- low blood cell counts;

- rash;

- hair loss; or

- feeling tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Sacituzumab govitecan side effects (more detail)

## Sacituzumab govitecan dosing information

Usual Adult Dose for Breast Cancer:

10 mg/kg IV once a week on Days 1 and 8 of 21-day treatment cycles
Maximum dose: 10 mg/kg per dose
Duration of therapy: Until disease progression or unacceptable toxicity
Use: For the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received 2 or more prior systemic therapies, at least 1 of them for metastatic disease

Usual Adult Dose for Urothelial Carcinoma:

10 mg/kg IV once a week on Days 1 and 8 of 21-day treatment cycles
Maximum dose: 10 mg/kg per dose
Duration of therapy: Until disease progression or unacceptable toxicity
Comments:
-This indication is approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent on verification and description of clinical benefit in a confirmatory trial.
Use: For the treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor

Detailed Sacituzumab govitecan dosage information

## What other drugs will affect sacituzumab govitecan?

Other drugs may affect sacituzumab govitecan, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Sacituzumab govitecan drug interactions (more detail)

## Where can I get more information?

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

## More about sacituzumab govitecan

- Check interactions
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- En español

### Patient resources

- Advanced Reading

#### Other brands

Trodelvy

### Professional resources

- Prescribing Information

### Related treatment guides

- Breast Cancer
- Urothelial Carcinoma

## Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright 1996-2023 Cerner Multum, Inc. Version: 2.01.